Pharsight

Drugs that contain Deucravacitinib

1. Sotyktu patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE47929 BRISTOL Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
Nov, 2033

(9 years from now)

US10000480 BRISTOL Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
Nov, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11021475 BRISTOL Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
Nov, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 09, 2027

NCE-1 date: 09 September, 2026

Market Authorisation Date: 09 September, 2022

Treatment: Treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Dosage: TABLET;ORAL

More Information on Dosage

SOTYKTU family patents

Family Patents